vintafolide investigational targeted cancer therapeutic currently development endocyte merck small molecule drug conjugate consisting small molecule targeting folate receptor overexpressed certain cancers ovarian cancer potent chemotherapy drug vintafolide designed deliver toxic vinblastine drug selectively cells expressing folate receptor using folate developed companion imaging agent etarfolatide identifies patients express folate receptor thus would likely respond treatment phase study evaluating vintafolide treatment platinumresistant ovarian cancer proceed trial phase studytarget trial nonsmallcell lung carcinoma nsclc ongoing marketing authorization application maa filing vintafolide etarfolatide treatment patients folate receptorpositive platinumresistant ovarian cancer combination doxorubicin pegylated liposomal doxorubicin pld accepted european medicines drug received orphan drug status europe march merck co acquired development marketing rights experimental cancer drug endocyte april endocyte remains responsible development commercialization etarfolatide noninvasive companion imaging agent used identify patients expressing folate receptor likely respond treatment merck endocyte stopped latestage study proceed vintafolide treating ovarian cancer recommendation data safety monitoring board saying drug failed improve progressionfree folate required cell division rapidly dividing cancer cells often express folate receptors order capture enough folate support rapid cell growth elevated expression folate receptor occurs many diseases including aggressively growing cancers inflammatory vintafolide binds folate receptor subsequently taken cell natural internalization process called endocytosis inside cell vintafolide linker releases chemotherapy drug kills httpsenwikipediaorgwikivintafolide